Fat mass during the treatment period increased only in the insulin-treated group, where the change in fat mass was higher compared to that of the CTRL and the NASH-STZ groups at study termination (p < 0.0001, Table 3). The gene discussed is INS; the disease is metabolic dysfunction-associated steatohepatitis.